+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Blood Glucose Monitoring Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175383
  • Report
  • August 2020
  • Region: North America
  • 95 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Agamatrix Inc.
  • Ascensia Diabetes Care
  • Dexcom
  • Johnson & Johnson
  • Medtronic
  • MORE
According to the American Diabetes Association (ADA), in 2018, almost 29 million people suffered from diabetes in the US, with around 1.3 million registered cases for Type 1 diabetes and another 84.1 million people displaying prediabetic symptoms that puts them at increased risk of developing type 2. ​The rates of newly diagnosed cases of Type 1 and Type 2 diabetes in the US have witnessed a spike in recent years with nearly 40,000 new cases being registered each year alone for Type 1 diabetes.​ To enhance the quality of medical services and the effectiveness of the administered treatments, diabetes monitoring and prevention agencies such as the ADA is investing significant resources towards the R&D of new medical devices for controlling the outbreak and enhance the life expectancy of the diabetic patients.​ In 2018, the ADA funded 318 new and continuing projects targeting all types of diabetes and its many complications, across a broad spectrum of scientific approaches. ​

Key Market Trends

The Blood Glucose Test Strips Revenue Consists of up to 79% Share in the Self-monitoring Blood Glucose Market

Type 1 diabetic patients should test their blood glucose at least three times a day, based on which the administered insulin dosages alter accordingly. The glucometer is a one-time purchase, however, the test strips, on the other hand, are a continuous investment, as a test strip needs to be disposed of after one use. Thus, it presents a considerable cost impact to the consumers. ​ The test strip market held 86.3% of the self-blood glucose monitoring market in 2019. CGM proves to be an instrumental tool for patients relying on insulin pumps or multiple daily injections (MDI) therapy, as it helps in the improvement of glycemic balance without aggregating the danger for severe hypoglycemia. The growth in market volume and share of strips are expected to be higher than that of glucose meters, because of the difference in use-case frequency. The average efficiency of glucose meter ranges between six months to three years, whereas test strips are for one-time use.

The United States Leads the Blood Glucose Monitoring Market

In 2019, the United States held the largest share in the blood glucose monitoring market, due to the large patient pool and broader acceptance of advanced technologies. The increase in the blood glucose monitoring market is due to the rise in the diabetes population in all age groups. The market value in the United States is expected to cross USD 10 billion by 2025. Diabetes-related complications are mostly due to poor glucose control. In the United States, the BGM Market is expected to record an approximate CAGR of 13% till 2025. Glucometers are now portable and accurate to use. Also, other factors, such as technological innovations and advances, give many conveniences in measuring blood glucose levels. One such advancement is in monitoring the blood glucose levels established with continuous glucose monitoring devices. In the United States, the new innovations from start-up companies having approximately 2.9 billion funding in diabetes industry like Glooko, OneDrop, verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc., these companies drive the United States Blood Glucose Monitoring Market.​

Competitive Landscape

The North American blood glucose monitoring market was dominated by a few major players in 2019, like Dexcom, Abbott, and Medtronic. It is expected that a new player may enter the market during the forecast period. In the United States, Dexcom holds more than 60% of the market in the year 2019. The innovations in devices driving the market like, in June 2018, the US Food and Drug Administration (FDA) approved the first implantable continuous glucose monitoring (CGM) device for people with Type 1 and Type 2 diabetes. The device, called the Eversense Continuous Glucose Monitoring System, provides monitoring for up to three months, and it’s approved for people aged 18 and above.​

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Agamatrix Inc.
  • Ascensia Diabetes Care
  • Dexcom
  • Johnson & Johnson
  • Medtronic
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation
5.1 Type
5.1.1 Self-monitoring Blood Glucose Devices
5.1.1.1 By Component (Value and Volume, 2012 - 2025)
5.1.1.1.1 Glucometer Devices
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.2 Continuous Glucose Monitoring
5.1.2.1 By Component (Value and Volume, 2012 - 2025)
5.1.2.1.1 Sensors
5.1.2.1.2 Durables
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012 - 2025)
5.2.1.1.1 Self-monitoring Blood Glucose
5.2.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.1.2 Continuous Glucose Monitoring
5.2.1.1.2.1 By Component (Sensors and Durables)
5.2.1.2 Canada (Value and Volume, 2012 - 2025)
5.2.1.2.1 Self-monitoring Blood Glucose
5.2.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.2.2 Continuous Glucose Monitoring
5.2.1.2.2.1 By Component (Sensors and Durables)
5.2.1.3 Rest of North America (Value and Volume, 2012 - 2025)
5.2.1.3.1 Self-monitoring Blood Glucose
5.2.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.3.2 Continuous Glucose Monitoring
5.2.1.3.2.1 By Component (Sensors and Durables)

6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2025)
6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott Diabetes Care
7.1.2 F. Hoffmann-La Roche AG
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Diabetes Care
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Dexcom
  • Medtronic
  • Arkray
  • Ascensia Diabetes Care
  • Agamatrix Inc.
  • Bionime Corporation
  • Acon
  • Medisana
  • Trivida
  • Rossmax
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll